Showing 2991-3000 of 6035 results for "".
- Phase 3 Data Show Port Delivery System With Ranibizumab Enabled Over 98% of Patients to Go 6 Months Between Treatments for Wet AMDhttps://modernod.com/news/phase-3-data-show-port-delivery-system-with-ranibizumab-enabled-over-98-of-patients-to-go-6-months-between-treatments-for-wet-amd/2478061/Genentech announced detailed results from the phase 3 Archway study evaluating its investigational Port Delivery System with ranibizumab (PDS) for the treatment of wet age-related macular degeneration (AMD). In Archway, 98.4% of PDS patients were able to go 6 months without needing additio
- AGTC Announces Updated Development Plan for its X-Linked Retinitis Pigmentosa Clinical Programhttps://modernod.com/news/agtc-announces-updated-development-plan-for-its-x-linked-retinitis-pigmentosa-clinical-program/2478058/Applied Genetic Technologies Corporation announced next steps in the clinical development of the company’s potential treatment of X-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene following receipt of written feedback from the FDA. The revised development p
- Synairgen’s Inhaled Interferon Beta Cuts Chance of Developing Severe COVID-19 Diseasehttps://modernod.com/news/synairgens-inhaled-interferon-beta-cuts-chance-of-developing-severe-covid-19-disease/2478043/Synairgen announced Monday that its inhaled formulation of interferon beta, dubbed SNG001, significantly reduced the chance of developing severe disease compared to placebo in hospitalized COVID-19 patients. Chief study investigator Tom Wilkinson remarked “the results confirm our belief tha
- A Potential New Approach to Combat Drug Resistance in Age-Related Macular Degenerationhttps://modernod.com/news/a-potential-new-approach-to-combat-drug-resistance-in-age-related-macular-degeneration/2478031/An international team of researchers led by Baylor College of Medicine and Houston Methodist has discovered a strategy that can potentially address a major challenge to the current treatment for choroidal neovascularization (CNV), according to a university news release. Anti-vascular endot
- Searchable Contact Lens Database Launched in U.S.https://modernod.com/news/searchable-contact-lens-database-launched-in-u-s/2478010/For the first time, the searchable contact lens database for eye care practitioners—the Contact Lens Compendium—is accessible in the United States. With the launch of the U.S. version (https://compendium.contactlensupdate.com/us), ECPs now
- Arctic Vision Announces $32 Million in Series A to Expand and Develop Ophthalmology Pipelinehttps://modernod.com/news/arctic-vision-announces-32-million-in-series-a-to-expand-and-develop-ophthalmology-pipeline/2478009/Arctic Vision, a clinical-stage biotechnology company incubated by Nan Fung Life Sciences and Pivotal BioVenture Partners China in 2019, announced its $32 million Series A financing led by Morningside Ventures, together with its existing investors. Arctic Vision focu
- Ocutrx Says It Will Deliver World’s First 5G AR/XR Medical Specific Platform in 2021https://modernod.com/news/ocutrx-says-it-will-deliver-worlds-first-5g-ar-xr-medical-specific-platform-in-2021/2477980/Ocutrx Vision Technologies announced plans to deliver the first AR headsets specific for medical applications providing connectivity from AT&T and using 5G products from Qualcomm Technologies. Ocutrx is building its AR/XR medical device, the Oculenz headset, for patient use; and a seco
- Apple Was Already Developing Handwashing Sensing Before COVID-19 Hithttps://modernod.com/news/apple-was-already-developing-handwashing-sensing-before-covid-19-hit/2477981/When Apple vice president of technology Kevin Lynch announced at WWDC last week that Apple Watch would add an automatic handwashing-detection feature in its next update, many people naturally assumed the feature was prompted by the COVID-19 pandemic – a public health emergency that has strongly u
- STAAR Surgical’s EVO Viva Presbyopia Correcting Lens Receives CE Mark Approvalhttps://modernod.com/news/staar-surgicals-evo-viva-presbyopia-correcting-lens-receives-ce-mark-approval/2477977/STAAR Surgical announced that its EVO Viva presbyopia correcting implantable collamer lens (ICL) has been approved for sale. STAAR received CE Mark approval of the presbyopic indication for its EVO+ Visian ICL with Aspheric (EDOF) Optic, commercially marketed as “EVO Viva,” from its European Noti
- Nova Eye Medical Acquires Molteno3 Glaucoma Drainage Device Portfoliohttps://modernod.com/news/nova-eye-medical-acquires-molteno3-glaucoma-drainage-device-portfolio/2477974/Nova Eye Medical has completed the acquisition of ophthalmic assets from Molteno Ophthalmic Limited, including the proprietary Molteno3 glaucoma drainage device (GDD) platform. Terms of th